Tagged with Investment

China The latest reporting on China biopharma dealmaking from MSQ Ventures, including the Top 10 biotech in-licensing deals in H1 2021, the Top 5 out-licensing deals, and Top 10 IPOs.   Made with Visme Infographic Maker Made with Visme Infographic Maker Made with Visme Infographic Maker

Denmark Tore von Würden talks through Amgen Denmark’s focus areas of osteoporosis, cardiovascular disease, haematology, and oncology, where it hopes not only to provide medicines but also contribute to the overall ecosystem. von Würden also explains the logic and relevance of the company’s M&A activity in Denmark in recent years, highlights…

China The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year on from allowing pre-revenue biotechs to list on HKEX; and another big global investment from Swiss CDMO Lonza, this time…

CEE The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies are looking to invest in CEE; how Polish vaccine scepticism has benefited Australia; and Hungary’s manufacturing tie-up with Chinese Sinopharm.…

Europe The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching above their weight. This data is taken from the 2021 edition of the EFPIA’s comprehensive annual data review of the European pharma…

Saudi Arabia Dr Ahmed Alaskar is executive director of the King Abdullah International Medical Research Center (KAIMRC); president of the Saudi Society of Blood and Marrow Transplantation (SSBMT); professor of Consultant Adult Hematology & HSCT at King Saud bin Abdulaziz University for Health Sciences; and chairman of the Riyadh Global Medical Biotechnology…

Saudi Arabia Looking to diversify its economy while simultaneously improving its healthcare system, Saudi Arabia has been rolling out incentives for international companies to invest in local manufacturing. Here are three trends that the Kingdom hopes will catch the attention of global biopharma and generics investors.   With the aim of creating…

Denmark The Danish Life Science Cluster is Denmark’s new national business cluster for life science technology, established in December 2020 with the goal of strengthening collaboration between the country’s public and private sectors and commercialising more of the discoveries being made in its world-class research universities. The Cluster’s director, Diana Arsovic…

Turkey The president of the Investment Office of the Presidency of the Republic of Turkey, Burak Dağlıoğlu, outlines the country’s current economic situation after posting the second-highest GDP growth among G20 countries in 2020, highlights the crucial role of the life sciences industry during the pandemic and the opportunities available for…

Denmark Healthcare DENMARK is a non-profit organization and public-private partnership representing Danish healthcare stakeholders internationally. Jakob Skaarup Nielsen, its CEO, highlights the Nordic country’s “treasure trove” of health data, the efforts to digitalize even further and the population’s open mind when it comes to participating in clinical trials. Moreover, he outlines…

Europe Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the innovative European pharma industry in building a healthier future for the continent’s citizens in the wake of the COVID-19 pandemic.…

Turkey Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies interested in Turkey, and the objective of reaching one billion dollars in revenue. In addition, he outlines Abdi’s international ambitions…